Status:

COMPLETED

Nasal Oxygen Therapy After Cardiac Surgery

Lead Sponsor:

Papworth Hospital NHS Foundation Trust

Collaborating Sponsors:

University Hospitals, Leicester

King's College London

Conditions:

Cardiac Valve Disease

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

NOTACS aims to determine if prophylactic use of high-flow nasal therapy (for a minimum of 16 hours after tracheal extubation, inclusive of up to one hour off randomised therapy for transfers around th...

Detailed Description

Patients undergoing cardiac surgery are at significant risk of postoperative pulmonary complications that may lead to prolonged ICU and hospital stay and increase mortality. The incidence of respirato...

Eligibility Criteria

Inclusion

  • Aged 18 years or over.
  • Undergoing any elective or urgent first-time or redo cardiac surgery performed on cardiopulmonary bypass
  • Have one or more clinical risk factors for postoperative pulmonary complications (COPD, asthma, lower respiratory tract infection in last 4 weeks as defined by use of antibiotics, body mass index ≥35 kg/m2 , current (within the last 6 weeks) heavy smoker (\> 10 pack years)) (47, 48).
  • Asthma is a disease characterized by recurrent attacks of breathlessness and wheezing, and patients will have been prescribed medication by inhalers or nebulisers (either bronchodilators or steroids).
  • Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow. The more familiar terms 'chronic bronchitis' and 'emphysema' are no longer used but are now included within the COPD 13 diagnosis. The most common symptoms of COPD are breathlessness, or a 'need for air', excessive sputum production, and a chronic cough. Patients suitable for the NOTACS study will have been prescribed medication by inhalers or nebulisers (either bronchodilators or steroids).

Exclusion

  • Requiring home oxygen therapy.
  • Deep hypothermic circulatory arrest planned
  • Contraindication to HFNT, e.g. nasal septal defect.
  • Requirement for home ventilatory support (including: HFNT, CPAP, BiPAP)
  • Requiring emergency cardiac surgery defined as surgery required within 24 hours of the decision to operate.
  • Patients not fluent in English.

Key Trial Info

Start Date :

September 8 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 6 2024

Estimated Enrollment :

1280 Patients enrolled

Trial Details

Trial ID

NCT05308719

Start Date

September 8 2020

End Date

December 6 2024

Last Update

May 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Royal Papworth Hospital NHS Foundation Trust

Cambridge, Cambridgeshire, United Kingdom, CB20AY

Nasal Oxygen Therapy After Cardiac Surgery | DecenTrialz